Literature DB >> 11204738

Expression and regulation of prostaglandin E receptor subtype mRNAs in rat sensory ganglia and spinal cord in response to peripheral inflammation.

L F Donaldson1, P S Humphrey, S Oldfield, S Giblett, B D Grubb.   

Abstract

Prostaglandins are known to act via seven transmembrane domain receptors to exert actions on both peripheral and central neurons resulting in changes in neuronal excitability. Prostaglandin E2, the prostaglandin most often associated with inflammation, itself acts on a family of closely related receptors, the EP receptors. Using semi-quantitative reverse transcription polymerase chain reaction (RT-PCR), we have shown that rat primary afferent neurons express the mRNA for all EP receptor subtypes, and that some, but not all EP receptor subtype mRNAs are down-regulated in sensory neurons in response to an acute peripheral inflammation. We also show for the first time that all EP receptor subtype mRNAs are expressed in rat lumbar spinal cord. Spinal cord EP receptor subtype mRNAs are also regulated in acute inflammation in a pattern distinct from the changes seen in sensory ganglia in response to the same inflammatory stimulus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11204738     DOI: 10.1016/s0090-6980(00)00101-5

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  8 in total

1.  Prostaglandin E(2) inhibits calcium current in two sub-populations of acutely isolated mouse trigeminal sensory neurons.

Authors:  Stephanie L Borgland; Mark Connor; Renae M Ryan; Helen J Ball; MacDonald J Christie
Journal:  J Physiol       Date:  2002-03-01       Impact factor: 5.182

2.  The prostaglandin E2 receptor, EP2, is upregulated in the dorsal root ganglion after painful cervical facet joint injury in the rat.

Authors:  Jeffrey V Kras; Ling Dong; Beth A Winkelstein
Journal:  Spine (Phila Pa 1976)       Date:  2013-02-01       Impact factor: 3.468

3.  The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache.

Authors:  Maria Antonova; Troels Wienecke; Karen Maubach; Emma Thomas; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2011-06-17       Impact factor: 7.277

4.  Co-induction of cyclooxygenase-2 [correction of cyclooxyenase-2] and early growth response gene (Egr-1) in spinal cord in a clinical model of persistent inflammation and hyperalgesia.

Authors:  Sharron Dolan; Peter Hastie; Claire Crossan; Andrea M Nolan
Journal:  Mol Pain       Date:  2011-11-23       Impact factor: 3.395

5.  EP1 receptor within the ventrolateral periaqueductal grey controls thermonociception and rostral ventromedial medulla cell activity in healthy and neuropathic rat.

Authors:  Enza Palazzo; Francesca Guida; Luisa Gatta; Livio Luongo; Serena Boccella; Giulia Bellini; Ida Marabese; Vito de Novellis; Francesca Rossi; Sabatino Maione
Journal:  Mol Pain       Date:  2011-10-24       Impact factor: 3.395

6.  Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study.

Authors:  Pascal F Durrenberger; Paul Facer; Maria A Casula; Yiangos Yiangou; Roy A Gray; Iain P Chessell; Nicola C Day; Sue D Collins; Sharon Bingham; Alex W Wilson; David Elliot; Rolfe Birch; Praveen Anand
Journal:  BMC Neurol       Date:  2006-01-04       Impact factor: 2.474

7.  Nerve growth factor mediates a switch in intracellular signaling for PGE2-induced sensitization of sensory neurons from protein kinase A to Epac.

Authors:  Michael R Vasko; Ramy Habashy Malty; Chunlu Guo; Djane B Duarte; Yihong Zhang; Grant D Nicol
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

8.  Periaqueductal Grey EP3 Receptors Facilitate Spinal Nociception in Arthritic Secondary Hypersensitivity.

Authors:  R A R Drake; J L Leith; F Almahasneh; J Martindale; A W Wilson; B Lumb; L F Donaldson
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.